Similarly, an in vitro experiment showed that crizotinib can be used to treat peritoneal spread of pancreatic cancer based on inhibition of cell proliferation and metastasis mediated by phosphorylation of the c-Met pathway (Takiguchi et al., 2017). This evidence concerns the gene MET and pancreatic neoplasm.